AngioDynamics, Inc. (NASDAQ:ANGO) is Acuitas Investments LLC’s 6th Largest Position

Acuitas Investments LLC raised its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 9.7% in the first quarter, HoldingsChannel reports. The fund owned 442,230 shares of the medical instruments supplier’s stock after purchasing an additional 38,950 shares during the period. AngioDynamics accounts for approximately 3.5% of Acuitas Investments LLC’s investment portfolio, making the stock its 6th largest holding. Acuitas Investments LLC’s holdings in AngioDynamics were worth $4,153,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Systematic Financial Management LP boosted its holdings in AngioDynamics by 4.6% during the fourth quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier’s stock worth $23,093,000 after buying an additional 110,719 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of AngioDynamics by 10.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier’s stock worth $13,636,000 after acquiring an additional 135,007 shares during the period. Segall Bryant & Hamill LLC raised its position in shares of AngioDynamics by 55.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock worth $12,963,000 after acquiring an additional 503,713 shares during the period. Nuveen Asset Management LLC grew its position in shares of AngioDynamics by 37.4% during the 4th quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier’s stock valued at $11,875,000 after acquiring an additional 353,070 shares during the period. Finally, Royce & Associates LP grew its position in shares of AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after acquiring an additional 133,312 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective (up from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $9.48 on Wednesday. The firm has a 50 day simple moving average of $9.87 and a 200-day simple moving average of $10.05. The firm has a market cap of $385.06 million, a price-to-earnings ratio of -9.37 and a beta of 0.60. AngioDynamics, Inc. has a one year low of $5.47 and a one year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 14.61% and a negative return on equity of 3.73%. The firm had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. The firm’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.